Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
Kim Hørslev-Petersen, Merete Lund Hetland, Peter Junker, Jan Pødenphant, Torkell Ellingsen, Palle Ahlquist, Hanne Lindegaard, Asta Linauskas, Annette Schlemmer, Mette Yde Dam, Ib Hansen, Hans Christian Horn, Christian Gytz Ammitzbøll, Anette Jørgensen, Sophine B Krintel, Johnny Raun, Julia S Johansen, Mikkel Østergaard, Kristian Stengaard-Pedersen, OPERA study-group
Annals of the Rheumatic Diseases Apr 2014, 73 (4) 654-661; DOI: 10.1136/annrheumdis-2012-202735